American small and medium-size companies that rely on China are scrambling to adjust their business plans in response to the escalating trade war.Traderead more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
The summit comes amid fears over a global economic slowdown, and U.S. tensions over trade allies, Iran and Russia.Politicsread more
The world's second biggest economy is past a point where it cannot ignore its enormous debt anymore, according to an analyst.China Economyread more
As demand for lab monkeys continues to rise, U.S. scientists are reporting delays in research projects because they can't obtain enough animals, according to the National...Politicsread more
Trump does have some powerful tools that would not require approval from U.S. Congress.Politicsread more
The European Union will respond in kind if the U.S. imposes tariffs on France over digital tax plan, EU chief Donald Tusk told G-7.Technologyread more
Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Carl Medlock used to work at Tesla. Now he's one of the few people in the U.S. that can fix the company's original Roadster electric vehicles.Technologyread more
China said on Saturday it strongly opposes Washington's decision to levy additional tariffs on $550 billion worth of Chinese goods and warned the United States of consequences...Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
DaVita Medical Group operates nearly 300 clinics and half a dozen outpatient surgical centers in six states – Florida, California, Colorado, Washington, Nevada and New Mexico.
The DaVita facilities will become part of United's Optum division, the umbrella for all of the noninsurance side of the business: pharmacy benefits, data analytics, consulting, clinics and surgical centers and home care.
"I am so proud of the DaVita Medical Group accomplishments, including our excellent clinical outcomes," said Kent Thiry, DaVita chairman and CEO. "The combination of DaVita Medical Group and Optum should lead to even higher levels of performance."
Yet, for DaVita, the medical group has significantly underperformed the company's dialysis division. Last month, DMG posted a $5 million operating loss in the third quarter due to higher-than-expected medical costs, prompting the company to put the unit up for sale.
The DMG clinics would become part of Optum's already large outpatient medical care footprint across 60 markets nationally. After completing an earlier $2.3 billion acquisition of Surgical Care Affiliates, the network includes 30,000 affiliated physicians, about 200 urgent care clinics and 200 outpatient surgery centers.
"We are in the marketplace. We are continuing to look at assets that make sense to us, but we have put together, what I'd call solid models in terms of how we view the organizations and how they fit," Optum CEO Larry Renfro said last week at UnitedHealth's analyst day in New York.
Optum's integration of data analytics, pharmacy benefits and medical services has helped fueled UnitedHealth's growth through acquisitions. The DaVita deal marks its fourth and largest transaction this year.
Others in the industry are now vying to take a page from the Optum playbook.
This week, pharmacy benefits firm struck a in a bid to create a vertically integrated benefits and health-care system that would be anchored around CVS' in-store clinics and pharmacies. The companies say together they can provide consumers with better-coordinated and more cost-effective care.
While CVS and Aetna have little overlap, the proposed merger could encounter some regulatory scrutiny because of the scale of the deal. Until now, that kind of health-care model has generally been used by hospital systems such as Geisinger Health and Kaiser Permanente.
DaVita said it plans to focus on its kidney care business and use the proceeds of the sale for "significant stock repurchases" following the close of the transaction.
Still, the company does not plan on being a stand-alone business for long in an environment where there's pressure to provide greater value in health care.
"We also expect to pursue other investments in health-care services outside of kidney care," Thiry said.